Anti-Migraine Drugs Market By Drugs Type 2021 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Anti-Migraine Drugs Market
Anti-Migraine Drugs Market Analysis: By Drugs Type (Triptans and Ergot Alkaloids); and By Geography (Europe, APAC, North America and ROW) - With Forecast (2016-2021)
Report Code : HCR 0150
Updated Date: 26 February, 2016  

  • Report Description
  • Table of Contents
  • Customization Options
1. Anti-Migraine Drugs – Market Overview
2. Executive Summary
3. Anti-Migraine Drugs Market Landscape

   3.1. Market Share Analysis
   3.2. Comparative Analysis
      3.2.1. Product Benchmarking
      3.2.2. End User Profiling
      3.2.3. Top 5 Financials Analysis
4. Anti-Migraine Drugs – Market Forces
   4.1. Drivers
      4.1.1. Consistent rise in the incidence rates of migraine cases
   4.2. Restraints
   4.3. Opportunities
   4.4. Challenges
   4.5. Porter’s Five Forces Analysis
      4.5.1. Bargaining Power of Suppliers
      4.5.2. Bargaining Power of Buyers
      4.5.3. Threat of New Entrants
      4.5.4. Threat of Substitutes
      4.5.5. Degree of Competition
5. Anti-Migraine Drugs Market – Strategic Analysis
   5.1. Value Chain Analysis
   5.2. Pricing Analysis
   5.3. Opportunities Analysis
   5.4. Product/Market Life Cycle Analysis
   5.5. Suppliers and Distributors
6. Anti-Migraine Drugs Market, By Drugs Type
   6.1. Triptans
      6.1.1. Sumatriptan
      6.1.2. Zolmitriptan
      6.1.3. Rizatriptan
      6.1.4. Frovatriptan
      6.1.5. Others
   6.2. Ergot Alkaloids
7. Anti-Migraine Drugs Market, By Geography
   7.1. Europe
      7.1.1. Germany
      7.1.2. France
      7.1.3. Italy
      7.1.4. Spain
      7.1.5. Russia
      7.1.6. U.K.
      7.1.7. Rest of Europe
   7.2. Asia Pacific
      7.2.1. China
      7.2.2. India
      7.2.3. Japan
      7.2.4. South Korea
      7.2.5. Rest of Asia-Pacific
   7.3. North America
      7.3.1. U.S.
      7.3.2. Canada
      7.3.3. Mexico
   7.4. Rest of the World (RoW)
      7.4.1. Brazil
      7.4.2. Rest of RoW
8. Anti-Migraine Drugs – Market Entropy
   8.1. Expansion
   8.2. Technological Developments
   8.3. Merger & Acquisitions, and Joint Ventures
   8.4. Supply- Contract
9. Company Profiles
   9.1. Allergan
      9.1.1.  Introduction
      9.1.2. Financials
      9.1.3. Key Insights
      9.1.4. Key Strategy
      9.1.5. Product Portfolio
      9.1.6. SWOT Analysis
   9.2. Endo International Inc.
      9.2.1. Introduction
      9.2.2. Financials
      9.2.3. Key Insights
      9.2.4. Key Strategy
      9.2.5. Product Portfolio
      9.2.6. SWOT Analysis
   9.3. GlaxoSmithKline Plc     
      9.3.1.  Introduction
      9.3.2. Financials
      9.3.3. Key Insights
      9.3.4. Key Strategy
      9.3.5. Product Portfolio
      9.3.6. SWOT Analysis
   9.4. Pfizer Inc.    
      9.4.1. Introduction
      9.4.2. Financials
      9.4.3. Key Insights
      9.4.4. Key Strategy
      9.4.5. Product Portfolio
      9.4.6. SWOT Analysis
   9.5. Impax Laboratories Inc.  
      9.5.1. Introduction
      9.5.2. Financials
      9.5.3. Key Insights
      9.5.4. Key Strategy
      9.5.5. Product Portfolio
      9.5.6. SWOT Analysis
   9.6. Abbott Laboratories, Inc.    
      9.6.1. Introduction
      9.6.2. Financials
      9.6.3. Key Insights
      9.6.4. Key Strategy
      9.6.5. Product Portfolio
      9.6.6. SWOT Analysis
   9.7. Eisai, Inc. 
      9.7.1. Introduction
      9.7.2. Financials
      9.7.3. Key Insights
      9.7.4. Key Strategy
      9.7.5. Product Portfolio
      9.7.6. SWOT Analysis
   9.8. Eli Lilly and Company     
      9.8.1. Introduction
      9.8.2. Financials
      9.8.3. Key Insights
      9.8.4. Key Strategy
      9.8.5. Product Portfolio
      9.8.6. SWOT Analysis
   9.9. AstraZeneca plc
      9.9.1. Introduction
      9.9.2. Financials
      9.9.3. Key Insights
      9.9.4. Key Strategy
      9.9.5. Product Portfolio
      9.9.6. SWOT Analysis
   9.10. Dr. Reddy’s Laboratories     
      9.10.1. Introduction
      9.10.2. Financials
      9.10.3. Key Insights
      9.10.4. Key Strategy
      9.10.5. Product Portfolio
      9.10.6. SWOT Analysis
*More than 10 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"
10. Appendix
   10.1. Abbreviations
   10.2. Sources
   10.3. Research Methodology
   10.4. Bibliography
   10.5. Compilation of Expert Insights
   10.6. Disclaimer
Migraines are intense, sometimes debilitating headaches. It is an inherited tendency to have headaches with sensory disturbance. Migraine can be segmented into two major types as migraine with aura and migraine without aura and is more common in women than men due to frequent hormonal changes. Migraine is characterized by recurrent attacks of moderate to severe headaches along with other nervous system symptoms and that instability can become influenced by physiological changes like sleep, exercise and hunger. Apart from this other symptom includes disturbed vision, sensitivity to light, sound and smells, feeling sick and vomiting. This report is focused on identifying market size for anti-migraine drugs globally. Increasing instances of migraine related cases globally is one of the major drivers for the growth of the anti-migraine drugs coupled with increasing R&D activities and penetration of medical facilities to large part of global population.

This report identifies the anti-migraine drugs market size in for the year 2014-2016, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to anti-migraine drugs market.

Anti-Migraine Drugs Market

Globally North America dominated market for anti-migraine drugs in 2015 due to higher awareness about migraine and its effects and is estimated to continue the same during the period of study. North America was followed by Europe and Asia-Pacific as the second and third largest markets respective in 2015. Demand for anti-migraine drugs in the Asia-Pacific region is estimated to be grow fastest during the period of study and is expected to be driven by growing awareness about migraine in the region. This report on global anti-migraine drugs also covers different classes of anti-migraine drugs available and market size in various geographical regions.
  • On the basis of anti-migraine drug type this report classifies as follows covering all major types of drugs available in the market: Triptans (Sumatriptan, Zolmitriptan, Rizatriptan, Frovatriptan, Others) and Ergot Alkaloids
  • This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for anti-migraine drugs in each of the region.

Sample Companies Profiled in this Report are: 
  • Allergan
  • Endo International Inc.
  • GlaxoSmithKline Plc     
  • Pfizer Inc.    
  • Impax Laboratories Inc.
  • 10+
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports